Since the company is so honest and great, care to take a stab at why a PJ analyst knows that there will be an interim look during our most important trial ever after about 20-30% of patients have evented and why that has not become public knowledge? Just the company working honestly?
You know, because if you think bavi works and will repeat its stat. sig. survival benefit with only 200 patients (like I do), the difference is about 3 years in time to market with an interim look or without one. That's pretty flippin' material in my book for a company that is losing money every year.
That comment at the Cohen conference was the main reason I bought July call options. I thought the interim look would translate into some sort of official accelerated regulatory pathway like "fast-track" or "breakthrough" designation from an FDA trying to save face after such an ugly event last fall.
So while you're "LOL"ing at people for making claims about suing the company I'd say if something doesn't come public by end of next week that, very objectively speaking, it is a blatant violation of Reg FD. If they're just waiting for the FDA minutes to be final, great. However, when you start telling analysts who make public comments about it and don't disclose what the hell he's talking about publicly you are walking a very dangerous line.
And if that information was shared with institutions who bought on Friday and not with the public, how is that not acting on insider information?
I guess it's all IMO, but most of it is pretty factual.
